RxSight (RXST) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 25, 2026
AI-Generated Deep Dive Summary
RxSight (RXST) reported a 19% year-over-year decline in Q4 2025 total sales, driven by lower Light Delivery Device (LDD) sales and challenging comparisons to prior-year record placements. Despite the $32.6 million revenue drop, the company highlighted strong performance in its core business segment with Light Adjustable Lenses (LALs), which accounted for an all-time high 86% of quarterly sales. While overall net loss widened to $9.2 million, adjusted results showed improvement at $1.3 million after excluding stock-based compensation. Full-year revenue grew 4% to $134.5 million, driven by a 12% increase in LAL sales, though net losses rose due to lower-margin LDD revenue declines.
LAL unit sales reached 28,611 units in Q4, up 10% sequentially but down 2% year-over-year. This segment generated $28.2 million in revenue, unchanged from the prior year but reflecting a strong shift toward higher-margin products. Gross margin improved to 77.5%, up significantly from 71.6% a year ago, due to increased LAL sales and reduced reliance on lower-margin LDD units. Despite lower LDD sales—just 25 units globally compared to 83 in Q4 2024—the installed base of LDD units grew 17% to 1,134, indicating ongoing customer demand.
Looking ahead, RxSight expects 2026 revenue between $120 million and $135 million, down slightly from 2025's $134.5 million. The company anticipates weaker LDD sales in the near term but
Verticals
financeinvesting
Originally published on The Motley Fool on 2/25/2026